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Background:Aspirin, a commonly used antiplatelet agent, blocks platelet thromboxane A2 (TXA2) formation from
arachidonic acid (AA) by acetylating platelet cyclooxygenase-1 (COX-1). Laboratory methods currently used to
detect this antiplatelet effect of aspirin provide variable results. We have reported three methods that assess
platelet COX-1 acetylation (inactivation) by aspirin and its direct consequences. The ﬁrst and second assays
use monoclonal anti-human-COX-1 antibodies that only detect acetylated (inactivated) COX-1 and active
(non-acetylated) COX-1, respectively. The third method measures platelet production of TXB2 (the stable
metabolite of TXA2) in vitro in response to AA. We compared the results of these three reference methods
with other routinely used methods for assessing the functional consequences aspirin treatment.
Methods: 108 healthy volunteers were treated with low-dose aspirin for 7 days. On day 7 following aspirin
treatment COX-1 in the platelets was fully acetylated whereas only non-acetylated COX-1 was present in the
day 0 platelets. Further, TXB2 production by day 7 platelets was completely blocked. The following tests were
performed on the samples obtained from study participants before and after seven days of aspirin treatment:
PFA-100 closure time with collagen/epinephrine cartridge, VerifyNow® (VN) Aspirin Assay, platelet aggregation
and ATP secretion using AA, ADP, epinephrine and collagen as agonists.
Results: Comparing the pre-treatment and day 7 values, methods that use AA as platelet agonist (AA-induced
platelet aggregation/secretion and VN Aspirin Assay) showed high discriminative power. In contrast, results of
the other tests showed considerable overlap between day 7 and day 0 values.
Conclusions:Only assays that clearly distinguish between acetylated and non-acetylatedplatelet COX-1 are useful
for establishing the antiplatelet effect of aspirin. The other tests are not suitable for this purpose.© 2013 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Aspirin (acetylsalicylic acid) is widely used in the secondary
prevention of acute atherothrombotic events [1–6]. Although aspirin
is a general acetylating agent, its effect against arterial thrombosis
primarily depends on the acetylation of platelet cyclooxygenase 1onic acid; TXA2, thromboxane
ed COX-1; TXB2, thromboxane
w® Aspirin assay; PDP, Platelet
non-acetylated COX-1; anti-
PFA-100 collagen/epinephrine
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ical and Health Science Center,
, Hungary. Tel.: +36 52 431956;
).
. This is an open access article under(COX-1) at the side chain of Ser529 residue [2,7,8]. COX-1 converts
arachidonic acid (AA), released from plateletmembrane phospholipids,
into prostaglandin G2 and H2, the latter of which is then transformed to
thromboxane A2 (TXA2), a secondary platelet agonist. Ser529 is located
in the wall of the active-site cavity of COX-1. The formation of the Ser-
Oγ-C(acetylsalicylic acid carbonyl) bond, which occurs in a single
elementary step [9], prevents the access of AA to the active site and
consequently blocks the production of TXA2.
As aspirin is ineffective in preventing acute vascular events in some
patients the term “aspirin resistance” was introduced. Although aspirin
resistance is a poorly deﬁned term, it has beenwidely used and aPubMed
search on July 15, 2013 resulted in 1844 citations, including 500 reviews
[10–16]. Four aspects of “aspirin resistance” have been reported:
1/ Chemical (“true”) aspirin resistance: inability of aspirin to acetylate
platelet COX-1 at Ser529.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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measured by a laboratory test.
3/ A high platelet turnover in some instances results in an accelerated
production and release into the circulation of large numbers of
newly formed but not yet acetylated platelets [17–19].
4/ Clinical “aspirin resistance” where aspirin does not protect the
patient from an acute vascular event.
High platelet turnover, though might be of clinical importance,
should not be considered as aspirin resistance, since changing the
frequency of aspirin dosage overcomes the diminished response
to aspirin [20]. For clinical aspirin resistance the expression non-
responsiveness should be more appropriate. The failure of aspirin
to prevent acute atherothrombotic events in some patients
might not be related to the lack of COX-1 acetylation. Aspirin
is ineffective in inhibiting platelet activation induced by agonists
more potent than AA, e.g. high dose of collagen or thrombin.
Routinely used laboratory tests show high inter-, and intra-
individual variability and there is a considerable discrepancy
between results obtained by different tests. To assess these tests
one needs comparisons to reference methods, which might be too
sophisticated for everyday clinical use, but detect the acetylation
of platelet COX-1 with high certainty. Such a method was ﬁrst
developed in the seventies, in which inactivation of COX-1 by
aspirin was measured as a reduction in the ability of [3H-acetyl]-
aspirin to bind to a 85 kDa protein, COX-1, in the 180.000 g
supernatant of platelet lysate [21,22]. Most recently we developed
two methods that directly detect the acetylation or the lack of
acetylation of COX-1 in platelets by Western blotting [23]. The
methods utilize two monoclonal antibodies, one of which reacts
only with acetylated COX-1 (acCOX-1), while only the non-
acetylated form (nacCOX-1) is recognized by the other one. In
addition we designed a third method that measures the AA-
induced formation of thromboxane B2 (TXB2), the inactive
metabolite of TXA2, in platelet rich plasma (PRP) [23]. This method
determines the TXB2 producing capability of platelets and
indirectly detects the inhibition of COX-1 by aspirin. Although
these methods are too laborious for a routine laboratory, they are
well suitable for establishing the frequency of chemical aspirin
resistance in a population, and also for the evaluation of laboratory
methods routinely used for the detection of aspirin effect. Using the
aforementioned methods we demonstrated the lack of aspirin
resistance among 108 healthy volunteers taking 100 mg enteric-
coated aspirin daily for seven days [23]. This population was
utilized to evaluate several laboratory methods widely used
for the detection of aspirin effect, i.e., to reveal if these methods
diagnose false positive aspirin resistance in individuals with
platelet COX-1 fully acetylated by aspirin.Methods
Study Participants, Inclusion and Exclusion Criteria
Healthy individuals recruited for the study have been characterized in
a previous publication [23]. Ten individuals out of 121 recruited
volunteers were excluded on the basis of apriori exclusion criteria
(contraindications of aspirin treatment, chronic disease, known platelet
defect, and any medication in the preceding 2 weeks or during the
study, with the exception of oral contraceptives). Three participants did
not show up at the second blood sampling. The remaining study
population (n=108) had the following characteristics: 60 women and
48 men, mean age: 33.5 years (SD 9.3, range 19-59). 69.4% of them had
never smoked, 21.3% were current smokers. Study protocol was
approved by the National Ethics Committee and written informed
consent was obtained from all participants.Protocol of Aspirin Treatment and Blood Sample Collection
Study participants received 100 mg enteric-coated aspirin (Aspirin
protect, Bayer) once daily between 8 and 9 a.m. for 7 days. Compliance
was checked by pill count. In a single case, when non-compliance was
suspected, the seven-day period of aspirin treatment was repeated and
the intake of aspirin tablets was controlled by the study nurse. Blood
samples were collected into Vacutainer tubes containing 0.109 mol/L
trisodium citrate (Becton-Dickinson, Franklin Lakes, NJ) after overnight
fasting before and 168 hours after the ﬁrst dose of aspirin (day 0
and day 7 samples). PFA-100 closure time assay (Siemens, Marburg,
Germany) and VerifyNow® (VN) Aspirin assay (Accumetrics, San
Diego, CA) were performed on anti-coagulated whole blood. PRP was
separated by centrifugation (120 g, 37 °C, 15 min). Platelet depleted
plasma (PDP), was obtained by two consecutive centrifugations
(1500g, 25 °C, 20min).Reference Methods for the Detection of COX-1 Acetylation in Platelets
We developed reference methods for the direct and indirect
detection of COX-1 acetylation, which have been described in details
in a separate publication [23]. The ﬁrst two methods are based on
monoclonal antibodies generated against acetylated or non-
acetylated form of COX-1. The antibodies were raised against
protein-linked nonapeptides with the amino acid sequence that
corresponded to human COX-1 525-533 residues. Both unmodiﬁed
peptide ((H-Gly-Ala-Pro-Phe-Ser-Leu-Lys-Gly-Leu-OH) and peptide
acetylated at Ser 529 (H-Gly-Ala-Pro-Phe-Ser(Ac)-Leu-Lys-Gly-Leu-
OH) were used for the generation of monoclonal antibodies. By
selecting the appropriate clones two types of antibodies were
produced; one speciﬁc to non-acetylated COX-1 (anti-nacCOX-1)
and another one that reacted only with acetylated COX-1 (anti-
acCOX-1). Antibodies puriﬁed from ascites ﬂuid by Protein G afﬁnity
chromatography were used to detect the two forms of COX-1 by
Western blotting of platelet lysate. To our knowledge this is the
ﬁrst method that directly detects the state of acetylation of COX-1
in platelets.
The third reference method measures AA-induced generation of
TXB2 in PRP [23]. The method is based on the extraction of
generated TXB2 from PRP and its separation from AA that would
interfere with the assay, by solid phase extraction. The extracted
TXB2 is then, measured by the competitive immunoassay kit of
Assay Designs (Ann Arbor, MI). Its production was expressed as
pg TXB2/106 platelets.Routine Laboratory Tests of Platelet Function
Collagen/epinephrine (CEPI) cartridges were used for PFA-100
closure time measurements. VN Aspirin Assay was performed
according to the manufacturer’s instructions and the results were
expressed as Aspirin Reaction Units (ARU). Platelet aggregation
and secretion were followed in Chrono-Log 700 lumiaggregometer
(Chrono-Log, Havertown, PA) on PRP adjusted to 260 x 109/L platelet
count by PDP. Platelets were activated by either of the following
agonists: 500 μg/mL (1.53 mmol/L) AA (Helena, Gateshead, UK),
1 μg/mL ﬁbrillar collagen (Nycomed, Zurich, Switzerland), 10 μmol/L
ADP (Sigma Aldrich, St. Louis, MO), 10μg/mL (54.6μmol/L) epinephrine
(Gedeon Richter, Budapest, Hungary). Aggregation was recorded for
6min (ADP) or 8min (AA), or 10min (epinephrine and collagen) and
the results were expressed as percentage maximal change in light
transmission. ATP secretion of activated platelets was quantitated by
bioluminescence method using luciferin-luciferase reagent (Biothema
AB, Handen, Sweden). Maximal ATP secretion was expressed as μmol
ATP/1011 platelets.
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Variables were expressed as mean and SD or median, interquartile
range (IQR) and total range according to their distribution, established
by Kolmogorov-Smirnov test. Wilcoxon signed rank test was used to
analyze differences between day0 andday 7 values. Correlation analysis
was performed by Spearman test. Student t test was used to analyze
differences in variables between subgroups of individuals. SPSS version
16 (SPSS Inc., Chicago, Illinois) was used for statistical analyses.Fig. 2. Measurement of aspirin effect by PFA-100 closure time and VerifyNow Aspirin
assay. Citrated blood samples were obtained from healthy volunteers before the ﬁrst
dose of aspirin (day 0), and after the last dose of daily aspirin treatment for seven days
(day 7). Collagen-epinephrine (CEPI) cartridge was used for PFA-100 closure time
determination. The horizontal lines represent medians.Results
As demonstrated with two representative volunteers, only native
(non-acetylated) COX-1 was detected in day 0 platelet lysates whereas
only inactive (fully acetylated) COX-1 was detectable in the day 7
platelet lysates (Fig. 1). Based on our observation that the methods
used readily detects 2.5% of the platelet COX-1 content, no true aspirin
resistance was observed in this group of volunteers studied [23]. In
full agreement with the results above the AA-induced TXB2 production
measured on day 0 (median: 1140 pg TXB2/106 platelets, IQR: 854-
1396pg TXB2/106 platelets, total range: 372-2394pg TXB2/106 platelets)
decreased to its 1.4% (median: 16 pg TXB2/106 platelets, IQR: 12-19 pg
TXB2/106 platelets, total range: 4-35pg TXB2/106 platelets) by day 7. It
is to be noted that platelet count did not change during the one-week
aspirin treatment: at entry the mean platelet count was 271.3 (SD
62.5) x 109/L, on day 7 it was 278.5 (SD, 63.0) x 109/L.
As the reference methods clearly distinguished between pre-
treatment and day 7 values, and not even partial aspirin resistance
could be detected, we compared the results above for the day 0 and
day 7 platelets with the results obtained using routine laboratory tests
to evaluate the effects of aspirin on platelets. Although the statistical
analysis of PFA-100 CEPI closure times revealed signiﬁcant difference
between the two sets of results (p b 0.0001), there was a considerable
overlap and 41% of closure times of aspirin-treated individuals
remained in the pre-treatment “normal” range (Fig. 2, Table 1). If not
compared to the individual pre-treatment value, but to a reference
interval established for non-treated persons, in a high number of
cases, falsely, aspirin resistance would be diagnosed. In contrast, with
the exception of a single outlier, no overlap was observed between
day 0 and day 7 ranges by VN Aspirin Assay (Fig. 2). In the case of
PFA-100 method pre-treatment values correlated signiﬁcantly with
day 7 values, i.e., individuals with highly reactive platelets in the
absence of aspirin also showed relatively high platelet reactivityFig. 1. COX-1 acetylation by aspirin as detected by Western blotting using antibodies
reacting with acetylated (anti-acCOX-1) or non-acetylated COX-1 (anti-nacCOX-1).
Platelet lysates obtained from two representative healthy volunteers (V1, V2) before
(d0) and after 7 days (d7) of aspirin treatment were analyzed. As it has been published
in reference [23], the same results were obtained with all 108 volunteers involved in the
study.following aspirin treatment (Table 2). In the case of VN Aspirin Assay
no such correlation was observed.
We also investigated the effect of aspirin on agonist induced platelet
aggregation (Fig. 3, Table 1) and ATP release (Table 3) in the study
population. Using epinephrine as agonist, in 30% of the cases the low
pre-treatment values fell into the range of day 7. Similarly, in 26% of
individuals epinephrine-induced ATP release on day 0 was below the
limit of quantitation. Due to the signiﬁcant number of low responders
to epinephrine, this agonist is hardly suitable to estimate the effect of
aspirin. In the case of ADP aggregation, in spite of the statistically
signiﬁcant difference, the sets of day 0 and day 7 results were highly
overlapping (Fig. 3, Table 1). Even if the single low responder outlier
with 39% transmission increase (the lowest value on Fig. 2) was
eliminated, 94.4% of day 7 values overlapped the day 0 range. This result
demonstrates that in the absence of pre-treatment value from the same
individual, ADP aggregation gives false positive aspirin resistance in a
high number of cases. As the pre-treatment values of ADP induced
ATP release scattered in a wide range (Table 3) this parameter cannot
be used for testing the effect of aspirin, either. In the case of collagen-
induced aggregation and ATP secretion, 5% and 25% of the day 7 values
were above the lower limit of day 0 values, respectively. AA-induced
platelet aggregation (Fig. 3, Table 1) and ATP release (Table 3) showed
excellent distinctive power with no overlap between day 0 and day 7
ranges. The extent of ADP-, epinephrine- and collagen-induced platelet
aggregation measured on day 7 signiﬁcantly correlated with pre-
treatment values (Table 2). In the case of AA-induced aggregation no
such correlation was observed. It is to be noted that in a previous
study there was no correlation between AA induced TXB2 production
measured before and after 7days of aspirin treatment [23].Discussion
A number of laboratory methods are used to detect the effect of
aspirin on platelet function (see reviewed in references [14,15,24]).
This study compared the results of several routine platelet tests and
Table 1
Results of various platelet function tests in healthy volunteers before and after 7 days of aspirin treatment.
Assay method unit day 0 median
(IQR, total range)
day 7 median
(IQR, total range)
overlap of day 7 values
with the day 0 range
PFA-100 CEPI closure time sec 103
(90-116; 63-153)
177
(128-N300; 77-N300)
38.9%
VerifyNow Aspirin Assay ARU 657
(651-662; 586-671)
428
(407-467; 350-590)
0.9%
AA-induced aggregation ΔT% 80
(75-87; 50-99)
5
(4-6; 0-13)
0%
ADP-induced aggregation ΔT % 78
(72-85; 39-99)
66
(60-72; 16-91)
99.1%
Epinephrine-induced aggregation ΔT % 80
(52-87; 2-98)
21
(15-29; 3-73)
100%
Collagen-induced aggregation ΔT % 79
(72-85; 46-99)
9
(3-21; 0-52)
4.6%
Overlap for the PFA-100 assay was calculated as the percentage of day 7 values below the highest day 0 value. Overlap for aggregation induced by various platelet agonists and for the
VerifyNow assay was calculated as the percentage of day 7 values above the lowest day 0 value. AA: arachidonic acid, ARU: aspirin reaction unit, IQR: interquartile range, ΔT %:
ΔTransmission %.
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measure acetylation (inactivation) of platelet COX-1. As detailed in
Figs. 1, 2 and 3, only tests using AA as agonist clearly and without
equivocation differentiated platelets with native COX-1 from platelets
with inactive COX-1.
A signiﬁcant overlap between PFA-100 CEPI closure times of non-
treated and treated patients has also been reported by other authors
[25,26]. We also tested the PFA-100 closure time with collagen/ADP
cartridge, but the day 0 and day 7 results were fully overlapping and
they were not included in the manuscript. COX-1 independent
pathways, not inﬂuenced by aspirin, play an important role in the
formation of platelet plug at the aperture and the closure time reﬂects
the effect of aspirin only in some of the individuals. It is interesting
that the closure timesmeasured after aspirin treatment showed a highly
signiﬁcant correlation with the pretreatment closure times (Table 2).
This ﬁnding suggests that high pretreatment platelet reactivity
considerably inﬂuences the results and could overcome the effect of
aspirin in this assay. PFA-100 closure time is also inﬂuenced by von
Willebrand factor, hematocrit value and platelet count [24,27–29]. The
one-week aspirin treatment did not change the platelet count and it is
assumed that the two other variables did not change signiﬁcantly,
either.
The VN Aspirin Assay performed much better than the PFA-100
closure time with CEPI cartridge. This test uses AA as agonist to activate
platelets. The produced TXA2 initiates the biochemical signaling
pathway that ultimately transforms platelet glycoprotein IIb/IIIa
complex into a ﬁbrinogen binding receptor. Activated platelets then
bind to ﬁbrinogen-coated beads present in the cartridge, agglutinate
them resulting in increased light transmission. The blockade of TXA2
formation by aspirin prevents platelet activation and, consequently
the elevation of light transmission. The results are expressed as Aspirin
Reaction Units (ARU). According to the manufacturer’s instruction a
cut-off of b550 ARU is consistent with efﬁcient aspirin effect. InTable 2
Correlation between pre-treatment values and values obtained after 7 days of aspirin
treatment.
Assay method Correlation coefﬁcient (r) Signiﬁcance
PFA-100 CEPI closure time 0.577 p b 0.0001
VerifyNow Aspirin Assay 0.039 p=0.686
Arachidonic acid-induced aggregation 0.019 p=0.844
ADP-induced aggregation 0.561 p b 0.0001
Epinephrine-induced aggregation 0.483 p b 0.0001
Collagen-induced aggregation 0.259 p=0.007our study population, with a single exception (586 ARU), all pre-
treatment (day 0) values were above 600 ARU (Fig. 2). Seven days of
aspirin treatment brought down the response to AA in all, but one
(590 ARU) case, below 550 ARU. Thus, the VN Aspirin assay in 99% of
the cases reliably reﬂected the state of COX-1 acetylation in healthy
volunteers. There was no correlation between the day 0 and day 7
values (Table 2), i.e., the pre-treatment platelet reactivity did not
inﬂuence the effect of aspirin.
Light transmission aggregometry is a conventional technique to
detect platelet aggregation and, if a lumiaggregometer is available,
it can be supplemented by the determination of agonist induced
ATP secretion. This technique has been adapted to the detection of
aspirin effect and using various agonists it still enjoys considerable
popularity. As expected, AA that utilizes COX-1-dependent pathway
for aggregation/secretion had a high power in distinguishing platelet
samples with acCOX-1 and nacCOX-1 (Fig. 3). There was no overlap
between day 0 and day 7 results of AA-induced aggregation/secretion
i.e., the assay reliably reﬂected the state of COX-1 acetylation in healthy
volunteers. Exactly like in the case of VN Aspirin Assay the aggregabilityFig. 3. Measurement of aspirin effect by platelet aggregation. Epinephrine, ADP,
arachidonic acid (AA), and collagenwere used as agonists to induce aggregation inplatelet
rich plasma. Samples were obtained from healthy volunteers before the intake of the ﬁrst
dose of aspirin (day 0) and 24hours after the last dose of daily aspirin treatment for seven
days (day 7). Results were expressed as maximal changes in light transmission
(Δtransmission %) during aggregation. The horizontal lines represent median values.
Table 3
Agonist induced ATP release from platelets of healthy volunteers before and after 7days of
aspirin treatment.
Agonist μmol ATP/1011 platelets overlap of day 7 values
with the day 0 range
day 0 median
(IQR, total range)
day 7 median
(IQR, total range)
Arachidonic acid 1.1
(0.9-1.4; 0.4-2.6)
0
(0; 0)
0%
ADP 1.0
(0.7-1.2; 0-2.2)
0
(0; 0-0.8)
100%
Epinephrine 1.2
(0.2-1.5; 0-2.8)
0
(0; 0)
100%
Collagen 1.0
(0.8-1.3; 0.3-2.2)
0.2
(0.1-0.3; 0-1.9)
25.0%
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(Table 2).
Due to the low pre-treatment aggregation and secretory responses
to epinephrine in about a quarter of individuals [30,31], this agonist is
hardly suitable for the detection of aspirin effect (Fig 3, Table 3). In the
case of ADP induced aggregation/secretion the median day 7 values
were lower than the day 0 median values, however the considerable
overlap of the two sets of results excludes the correct evaluation of
aspirin effect. Changing the ADP concentration in the range of 2.5-
20 μM did not improve the power of this test to detect the effect of
aspirin (data not shown). Low dose (1 μg/mL) of collagen as agonist
had better distinguishing power than ADP. Using this agonist the
overlap of day 7 values with the range of pre-treatment values was
lower, but was not eliminated. Aggregation and ATP release induced
by ADP and collagen involve COX-1-independent mechanisms,
which may obscure the effect of aspirin. In these cases, just like in
the case of PFA-100 CEPI closure time, pre-treatment values were
signiﬁcant determinants of day 7 values, i.e. non-acetylated platelets
demonstrating high reactivity to the agonists also showed comparably
high reactivity while their COX-1 was fully acetylated and TXA2
production was blocked (Table 2).
The main reasons for the lack of aspirin effect on COX-1 acetylation
and platelet TXA2 production in patients, and probably also the main
reason for testing the effect of aspirin in the laboratory, is non-
compliance and the use of interfering non-steroid anti-inﬂammatory
drugs that prevent the access of aspirin to Ser529 in the active-site
cavity of COX-1 [32–35]. The expression of COX-2,which is not inhibited
by lowdose aspirin, in certain pathological conditions like inﬂammatory
diseases, might also be responsible for a diminished suppression of
platelet TXA2 production by aspirin [36–38], although the signiﬁcance
of such a mechanism has been debated [39]. The above possibilities
should not be considered as aspirin resistance and should be
speciﬁed, if COX-1 dependent diagnostic tests suggest the lack of
aspirin effect. Not counting our reference methods, AA-induced
platelet aggregation/secretion, VN Aspirin Assay and very likely
also serum TXB2 determination [40] are the assays that can be used
successfully for the detection of such conditions. PFA-100 CEPI
closure time and aggregation/secretion induced by agonists other
than AA do not seem to be reliable for such a purpose. However,
these assays, testing platelet functions that also involve COX-1-
independent pathways, might be useful in the detection of highly
reactive COX-1 acetylated platelets and might serve as predictors of
adverse clinical outcome [11,41]. However, this possibility should
be supported by large-scale clinical studies.Conﬂict of Interest Statement
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